MannKind reported $12.43M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Adma Biologics USD 1.63M 54K Dec/2025
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Halozyme Therapeutics USD 5.51M 597K Mar/2026
Insmed USD 20.08M 517K Mar/2026
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
MacroGenics USD 3.34M 2.54M Sep/2025
MannKind USD 12.43M 1.44M Mar/2026
Merck USD 479M 67M Mar/2026
Minerva Neurosciences USD 2.31M 60K Jun/2024
Novavax USD 5.82M 342K Dec/2025
Pfizer USD 671M 40M Mar/2026
Sanofi EUR 178M 203M Mar/2026
Xencor USD 4.7M 2.65M Mar/2026